Eiji Kita

A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing <i>Escherichia coli</i> O157:H7

Kiyotaka Nishikawa, Koji Matsuoka, Eiji Kita et al. · Proceedings of the National Academy of Sciences · 2002 · 197 citations · Full text

Toxinology, Immunology, Glycobiology +19

Oral Therapeutic Agents with Highly Clustered Globotriose for Treatment of Shiga Toxigenic<i>Escherichia coli</i>Infections

Miho Watanabe, Koji Matsuoka, Eiji Kita et al. · The Journal of Infectious Diseases · 2004 · 120 citations · Full text

Critical Role of NK Cells Rather Than Vα14+NKT Cells in Lipopolysaccharide-Induced Lethal Shock in Mice

Masashi Emoto, Mamiko Miyamoto, Izumi Yoshizawa et al. · The Journal of Immunology · 2002 · 82 citations

Innate Immune System, Immunology, Immune Regulation +20

Suppression of virulence factors of <i>Pseudomonas aeruginosa</i> by erythromycin

Eiji Kita, Masayoshi Sawaki, Daisuke Oku et al. · Journal of Antimicrobial Chemotherapy · 1991 · 80 citations

Erythromycin Stearate, Biosynthesis, Antimicrobial Susceptibility +14

A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin

Kiyotaka Nishikawa, Miho Watanabe, Eiji Kita et al. · The FASEB Journal · 2006 · 74 citations

Microbial Toxin, Protein Secretion, Biochemistry +15